
Releases
Marengo Secures ESMO Oral Presentation and Adds Key Pembrolizumab Expert
Clinical-stage biotech Marengo Therapeutics will present Phase 2 data from its STARt-001 study at the 2026 ESMO Congress, showcasing the efficacy of invikafusp alfa in patients resistant to PD-1 therapies. To steer this next development phase, the company has appointed former Merck oncology leader Dr. Eric Rubin to its advisory board.






















.png)


